News

FiercePharma14y
Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product (Lipegfilgrastim) in Breast Cancer P - Fierce Pharma
Lipegfilgrastim (XM22), a long acting granulocyte colony-stimulating factor (G-CSF), was added to Teva’s portfolio through the acquisition of ratiopharm.
FierceBiotech14y
Teva Announces Data on Granulocyte Colony Stimulating Factor Compounds for the Prevention of Chemotherapy-Induced Neutrope - Fierce Biotech
CG-10639 (formerly Neugranin) Phase II/III data demonstrated non-inferiority to pegfilgrastimDosing study of XM22 supported future Phase III trial of 6mg dose versus pegfilgrastimBoth compounds ...
FiercePharma14y
Teva Announces Data on Granulocyte Colony Stimulating Factor Compounds for the Prevention of Chemotherapy-Induced Neutrope
CG-10639 (formerly Neugranin) Phase II/III data demonstrated non-inferiority to pegfilgrastimDosing study of XM22 supported future Phase III trial of 6mg dose versus pegfilgrastimBoth compounds ...